Voyager Therapeutics Inc
NASDAQ:VYGR
| Market Cap (Intraday) | 162.61M |
| Current PE | 4.43 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $4.58 |
| 50-Day MA | $5.05 |
| 200-Day MA | $8.55 |
Voyager Therapeutics Inc Stock, NASDAQ:VYGR
75 Sidney Street, Cambridge, Massachusetts 02139
United States of America
Phone: +1.857.259.5340
Number of Employees: 179
Description
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.